Table 6 Clinical characteristics of thyroid dysfunction associated with PD-1 monoclonal antibody therapy in primary liver cancer
Clinical hyperthyroidism (n = 14) | Clinical hypothyroidism (n = 28) | P | t/ x2/Z | |
|---|---|---|---|---|
Gender (n, %) | 0.522 | 0.410 | ||
Male | 12(85.7) | 20(71.4) | ||
Female | 2(14.3) | 8(28.6) | ||
Age(years,x ± s) | 61.5 ± 9.9 | 57.1 ± 8.7 | 0.167 | 1.408 |
BMI | 24.9 ± 2.6 | 24.3 ± 3.9 | 0.698 | 0.394 |
Diabetes | 1.000 | 0.000 | ||
Yes | 3(21.4) | 5(17.9) | ||
No | 11(78.6) | 23(82.1) | ||
Evaluation time [weeks,M(Q1,Q3)] | 11.5(3.0, 30.0) | 11.0(3.0, 23.3) | 0.742 | 0.348 |
Hepatocellular carcinoma (n,%) | 0.545 | - | ||
Yes | 14(100.0) | 26(92.9) | ||
No | 0(0.0) | 2(7.1) | ||
Staging of BCLC system(n,%) | 1.000 | 0.000 | ||
B | 3(15.0) | 5(19.4) | ||
C | 13(85.5) | 23(80.6) | ||
HBV or HCV(n,%) | 14(77.4) | 24(85.0) | 0.283 | - |
Cirrhosis (n,%) | 13(80.5) | 25(87.8) | 1.000 | 0.000 |
Decompensation stage (n,%) | 3(23.1) | 17(68.0) | 0.022 | 5.238 |
Yes | 10(76.9) | 8(32.0) | ||
No | ||||
Previous or combined treatment (n,%) | 6(42.9) | 2(7.1) | 0.018 | 5.527 |
Surgical resection | 12(85.7) | 22(78.6) | 0.578 | 0.309 |
TAE or TACE | 8(57.1) | 14(50.0) | 0.662 | 0.191 |
Tumor ablation | 9(64.3) | 19(67.9) | 0.817 | 0.05 |
Targeted agent | 0(0.0) | 2(7.1) | 0.545 | - |
Systemic chemotherapy | 1(7.1) | 3(10.7) | 1.000 | 0.000 |
Radiotherapy | 0(0.0) | 4(14.3) | 0.283 | - |
Name of PD-1 monoclonal antibody (n,%) | 0.273 | 1.201 | ||
Sintilimab | 8(57.1) | 11(39.3) | ||
Camrelizumab | 6(42.9) | 17(60.7) | ||
Thyroid antibody (n,%) | 1.000 | 0.000 | ||
Positive | 2(40.0) | 3(27.3) | ||
Negative | 3(60.0) | 8(72.7) |